Commencement of Cultivation

Hellenic Dynamics PLC
11 October 2023
 

11 October 2023

 

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

 

Commencement of Cultivation

 

London, 11 October 2023, Hellenic Dynamics plc (LSE: HELD), a medical cannabis cultivator with a dedicated focus on producing tetrahydrocannabinol ("THC") dominant strains of medical cannabis flowers for the burgeoning European medical cannabis markets, is pleased to confirm the beginning of cultivation.

 

Following the announcement of 29 September 2023, Elgo Dimitra, the public research institute overseen by the Greek Ministry of Agriculture, has begun the cultivation of medical cannabis flowers for Hellenic Dynamics.

 

It is the intention of the Company to shortly update its website with a presentation of the site construction process to completion and a further announcement will be made to the market in due course.

 

 

Enquires: 

 


Hellenic Dynamics plc  

Davinder Rai

                                                           

+44 (0)20 3818 7850

davinder@hellenicdynamics.com

Cairn Financial Advisers LLP

Emily Staples / Jo Turner / Ed Downes

 

+44 (0)20 7213 0880

Peterhouse Capital

Lucy Williams / Charles Goodfellow

                                   

+44 (0)20 7469 0930

J&H Communications

George Hudson  

                                      

+44 (0)7803 603130

 

 

About Hellenic Dynamics plc

 
Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation and supply of THC ("tetrahydrocannabinol") - dominant strains of medical cannabis flowers, destined for the growing medical cannabis markets across Europe. Hellenic Dynamics' core strategy is to develop and operate its 40,000 square metre active cultivation licence from its 195,506 square metre facility located near Thessaloniki in Northern Greece. In full production, Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per annum.

 
Hellenic Dynamics will take advantage of its relatively low cost base resulting from a comparatively low cost of power, having its own running water supply and the labour rates for skilled and semi-skilled labour in Northern Greece.

 
25 European countries now allow medical cannabis via prescription and the European cannabis market is expected to reach €43.3 billion per annum by 2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and extracts are initially intended for export into Europe's largest market - Germany, in addition to other European markets including domestically in Greece.

 
As the first medical cannabis cultivator to obtain a listing on the main market for listed securities of the London Stock Exchange, Hellenic is significantly different to the number of CBD (Cannabidiol) related companies that have appeared over the recent years. Hellenic Dynamics cultivates THC-dominant medical cannabis flowers. THC-dominant medical cannabis products are only available via a medical prescription.
Medicinal cannabis has been approved for use both in the United Kingdom and Germany, plus 23 other European countries, for conditions including but not limited to  chronic pain, intractable chemotherapy-related nausea, anxiety, insomnia, Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and glaucoma.

For further information please visit our website 
www.hellenicdynamics.com  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings